TTR and polyneuropathy: Two other agents, inotersen (an antisense oligonucleotide) and patisiran (a micro-ribonucleic acid inhibitor) are injectable therapies classified as TTR gene silencers that are approved for the treatment of ATTRh polyneuropathy only, and act by reducing hepatic TTR production (77, 78).